Whiteside John, Grover Michael, Hitchcock Kristin, Kim Richard
Department of Family Medicine, Mayo Clinic, Scottsdale, AZ USA.
J Fam Pract. 2006 Sep;55(9):809-12.
No patient-oriented evidence supports pneumococcal revaccination of any patient (high-risk or otherwise). Antibody levels may be augmented by revaccination; however, the clinical efficacy of revaccination, even among high-risk patients, is unknown. Revaccination is recommended by the Advisory Committee on Immunization Practices (ACIP) in certain circumstances (strength of recommendation [SOR]: C, expert opinion based on physiology/bench research). Revaccination once appears to be safe, especially if provided 5 years or more after primary vaccination (SOR: B, based upon consistent results of cohort studies and nonrandomized prospective trials).
没有以患者为导向的证据支持对任何患者（高危或其他情况）进行肺炎球菌再次接种。再次接种可能会提高抗体水平；然而，再次接种的临床疗效，即使在高危患者中，也尚不清楚。免疫实践咨询委员会（ACIP）在某些情况下建议进行再次接种（推荐强度[SOR]：C，基于生理学/基础研究的专家意见）。再次接种一次似乎是安全的，特别是如果在初次接种后5年或更长时间进行（SOR：B，基于队列研究和非随机前瞻性试验的一致结果）。
